Only 10% of rare diseases have an FDA-approved therapy. This sobering statistic highlights why research is so imperative for patients with rare diseases. Clinical trials can be a crucial opportunity to access life-saving treatments. However, African-American, African-Canadian and Latino patients with rare diseases face significant underrepresentation in clinical trials. This lack of representation results in drugs…